Hotspot mutations in the ER ligand-binding domain (LBD), such as the D538G and Y537S, can provide tumor cells a growth advantage, suggesting that these ESR1 mutations, to an extent, may display innate resistance to CDK4/6 inhibitors. Here, CDK4 is linked to neoplasm.